Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 20:31 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001873465-26-000002 · ownership.xml · derivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 12:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantCommon Stock | 111,349 | $4.67 | $519,999.83 |
DisclosureSEC source: 0000950170-25-090196 · ownership.xml · nonDerivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 111,349 F1 · kind: Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. F2 · ownership.nature: Shares held by Spouse. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 12:34 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000950170-25-087700 · ownership.xml · derivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 12:39 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0000950170-24-078172 · ownership.xml · derivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 13:00 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-040137 · doc4.xml · derivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| December 09, 2022 Filed Dec 12, 2022 21:25 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 23,950 | $1.92 | $45,984.00 |
DisclosureSEC source: 0001209191-22-060693 · doc4.xml · nonDerivative · entry 2 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,000 F2 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.88 to $1.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 09, 2022 Filed Feb 17, 2023 23:40 UTC Amendment | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 23,950 | $1.92 | $45,984.00 |
DisclosureSEC source: 0000899243-23-005523 · doc4a.xml · nonDerivative · entry 2 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GTAM1 2012 LLC Disclosed balance after: 152,000 F2 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.88 to $1.98. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 08, 2022 Filed Dec 12, 2022 21:25 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 3,050 | $1.68 | $5,124.00 |
DisclosureSEC source: 0001209191-22-060693 · doc4.xml · nonDerivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,050 F1 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2022 Filed Feb 17, 2023 23:40 UTC Amendment | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 3,050 | $1.68 | $5,124.00 |
DisclosureSEC source: 0000899243-23-005523 · doc4a.xml · nonDerivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GTAM1 2012 LLC Disclosed balance after: 128,050 F1 · price: The price in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:42 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-053831 · doc4.xml · derivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2032-10-13 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) October 13, 2023 or (ii) the date of the next Annual Meeting of Stockholders of the Company; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Company or otherwise ceases to serve as a Director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | ConversionSeries B Preferred Stock · Derivative | 696,851 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-031104 · doc4.xml · derivative · entry 3 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GTAM1 2012 ADV LLC Disclosed balance after: 0 Underlying: Common Stock · 283,514 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | PurchaseCommon Stock | 125,000 | $8.00 | $1,000,000.00 |
DisclosureSEC source: 0000899243-21-031104 · doc4.xml · nonDerivative · entry 2 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GTAM1 2012 LLC Disclosed balance after: 125,000 F3 · ownership.nature: Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 29, 2021 Filed Aug 3, 2021 00:12 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | ConversionCommon Stock | 283,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-031104 · doc4.xml · nonDerivative · entry 1 Martell Christopher · CIK 0001873465 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By GTAM1 2012 ADV LLC Disclosed balance after: 283,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.